Daiken Medical Co., Ltd. (TYO:7775)
Japan
· Delayed Price · Currency is JPY 470.00
+4.00 (0.86%)
Mar 10, 2026, 11:27 AM JST
Daiken Medical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 10,167 | 9,951 | 9,750 | 9,137 | 8,540 | 7,861 | Upgrade
|
| Revenue Growth (YoY) | 1.57% | 2.06% | 6.71% | 6.99% | 8.64% | -7.77% | Upgrade
|
| Cost of Revenue | 6,223 | 5,855 | 5,768 | 5,607 | 4,856 | 4,503 | Upgrade
|
| Gross Profit | 3,944 | 4,096 | 3,982 | 3,530 | 3,684 | 3,358 | Upgrade
|
| Selling, General & Admin | 2,632 | 2,209 | 2,240 | 2,105 | 2,092 | 1,943 | Upgrade
|
| Research & Development | - | 332 | 249 | 316 | 382 | 448 | Upgrade
|
| Operating Expenses | 2,632 | 2,584 | 2,539 | 2,475 | 2,533 | 2,437 | Upgrade
|
| Operating Income | 1,312 | 1,512 | 1,443 | 1,055 | 1,151 | 921 | Upgrade
|
| Interest Expense | -11.07 | -9 | -4 | -3 | -3 | -3 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.96 | - | 2 | - | 1 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 6.64 | 6 | 5 | - | 3 | 38 | Upgrade
|
| EBT Excluding Unusual Items | 1,311 | 1,509 | 1,446 | 1,052 | 1,152 | 956 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 2 | - | - | - | Upgrade
|
| Asset Writedown | -6.08 | -2 | -5 | -28 | -1 | - | Upgrade
|
| Other Unusual Items | 1.02 | - | -8 | - | - | -12 | Upgrade
|
| Pretax Income | 1,305 | 1,507 | 1,435 | 1,024 | 1,151 | 944 | Upgrade
|
| Income Tax Expense | 323.62 | 410 | 447 | 312 | 320 | 269 | Upgrade
|
| Net Income | 981.12 | 1,097 | 988 | 712 | 831 | 675 | Upgrade
|
| Net Income to Common | 981.12 | 1,097 | 988 | 712 | 831 | 675 | Upgrade
|
| Net Income Growth | -7.19% | 11.03% | 38.76% | -14.32% | 23.11% | -21.42% | Upgrade
|
| Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade
|
| EPS (Basic) | 34.15 | 38.19 | 34.39 | 24.78 | 28.93 | 23.50 | Upgrade
|
| EPS (Diluted) | 34.15 | 38.19 | 34.39 | 24.78 | 28.93 | 23.50 | Upgrade
|
| EPS Growth | -7.19% | 11.03% | 38.76% | -14.32% | 23.11% | -21.42% | Upgrade
|
| Free Cash Flow | - | 954 | 1,393 | 791 | 931 | 300 | Upgrade
|
| Free Cash Flow Per Share | - | 33.21 | 48.49 | 27.53 | 32.41 | 10.44 | Upgrade
|
| Gross Margin | 38.79% | 41.16% | 40.84% | 38.63% | 43.14% | 42.72% | Upgrade
|
| Operating Margin | 12.90% | 15.19% | 14.80% | 11.55% | 13.48% | 11.72% | Upgrade
|
| Profit Margin | 9.65% | 11.02% | 10.13% | 7.79% | 9.73% | 8.59% | Upgrade
|
| Free Cash Flow Margin | - | 9.59% | 14.29% | 8.66% | 10.90% | 3.82% | Upgrade
|
| EBITDA | - | 1,744 | 1,657 | 1,322 | 1,465 | 1,177 | Upgrade
|
| EBITDA Margin | - | 17.53% | 16.99% | 14.47% | 17.15% | 14.97% | Upgrade
|
| D&A For EBITDA | 245.5 | 232 | 214 | 267 | 314 | 256 | Upgrade
|
| EBIT | 1,312 | 1,512 | 1,443 | 1,055 | 1,151 | 921 | Upgrade
|
| EBIT Margin | 12.90% | 15.19% | 14.80% | 11.55% | 13.48% | 11.72% | Upgrade
|
| Effective Tax Rate | 24.80% | 27.21% | 31.15% | 30.47% | 27.80% | 28.50% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.